Yipinhong Pharmaceutical Co Ltd banner

Yipinhong Pharmaceutical Co Ltd
SZSE:300723

Watchlist Manager
Yipinhong Pharmaceutical Co Ltd Logo
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Watchlist
Price: 41.45 CNY 4.09%
Market Cap: ¥18.7B

P/E

-43.6
Current
239%
Cheaper
vs 3-y average of 31.3

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-43.6
=
Market Cap
¥14.8B
/
Net Income
¥-429.6m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-43.6
=
Market Cap
¥14.8B
/
Net Income
¥-429.6m

Valuation Scenarios

Yipinhong Pharmaceutical Co Ltd is trading above its 3-year average

If P/E returns to its 3-Year Average (31.3), the stock would be worth ¥-29.8 (172% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-172%
Maximum Upside
No Upside Scenarios
Average Downside
161%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple -43.6 ¥41.45
0%
3-Year Average 31.3 ¥-29.8
-172%
5-Year Average 20.7 ¥-19.68
-147%
Industry Average 25.5 ¥-24.25
-159%
Country Average 29.6 ¥-28.18
-168%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
¥14.8B
/
Oct 2025
¥-429.6m
=
-43.6
Current
¥14.8B
/
Dec 2025
¥191.6m
=
77.4
Forward
¥14.8B
/
Dec 2026
¥257.8m
=
57.5
Forward
¥14.8B
/
Dec 2027
¥333m
=
44.5
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Peer Comparison

All Countries
Close

Market Distribution

Lower than 100% of companies in China
Percentile
0th
Based on 5 557 companies
0th percentile
-43.6
Low
0 — 17.1
Typical Range
17.1 — 57.7
High
57.7 —
Distribution Statistics
China
Min 0
30th Percentile 17.1
Median 29.6
70th Percentile 57.7
Max 43 569.3

Yipinhong Pharmaceutical Co Ltd
Glance View

Market Cap
18.7B CNY
Industry
Pharmaceuticals

Yipinhong Pharmaceutical Co Ltd has carved its niche in the pharmaceutical landscape of China, with its roots embedded deeply in the nation's flourishing healthcare sector. Known for its dedication to combining traditional Chinese medicinal practices with modern scientific research, the company stands out in an increasingly competitive market. Yipinhong's operations are centered around developing, manufacturing, and distributing a broad spectrum of medicinal products that adhere to the highest quality standards. By focusing on therapeutic areas such as respiratory, cardiovascular, and gastrointestinal health, they strategically align with the growing demand for reliable medicinal solutions. What makes Yipinhong truly distinctive is its investment in research and development that drives innovation. This focus not only ensures a continuous pipeline of new products but positions them as a leader in the integration of traditional remedies with cutting-edge pharmaceutical science. The company thrives on a business model that maximizes its robust distribution network, encompassing both domestic and international markets. Yipinhong capitalizes on its vast network of sales agents and partnerships with hospitals, clinics, and pharmacies to ensure its products reach consumers efficiently. This network amplifies their revenue streams by tapping into various segments within the pharmaceutical supply chain. Moreover, Yipinhong's strategic collaborations for research and development and their participation in healthcare industry events bolster their market presence and brand recognition. By maintaining a harmonious balance between traditional approaches and modern demands, Yipinhong not only captures a unique market position but also sets a benchmark in pharmaceutical excellence and innovation.

Intrinsic Value
8.85 CNY
Overvaluation 79%
Intrinsic Value
Price ¥41.45
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett